KR20180100652A - 크로멘 화합물 및 제2활성제의 조합물 - Google Patents

크로멘 화합물 및 제2활성제의 조합물 Download PDF

Info

Publication number
KR20180100652A
KR20180100652A KR1020187022783A KR20187022783A KR20180100652A KR 20180100652 A KR20180100652 A KR 20180100652A KR 1020187022783 A KR1020187022783 A KR 1020187022783A KR 20187022783 A KR20187022783 A KR 20187022783A KR 20180100652 A KR20180100652 A KR 20180100652A
Authority
KR
South Korea
Prior art keywords
group
compound
trifluoromethyl
carboxylic acid
chromen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187022783A
Other languages
English (en)
Korean (ko)
Inventor
존 제이. 탤리
바비 더블유. 샌디지
에두아르도 제이. 마르티네즈
Original Assignee
유클리세스 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유클리세스 파마슈티컬스 인코포레이티드 filed Critical 유클리세스 파마슈티컬스 인코포레이티드
Publication of KR20180100652A publication Critical patent/KR20180100652A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
KR1020187022783A 2016-01-08 2017-01-09 크로멘 화합물 및 제2활성제의 조합물 Ceased KR20180100652A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276713P 2016-01-08 2016-01-08
US62/276,713 2016-01-08
US201662277225P 2016-01-11 2016-01-11
US62/277,225 2016-01-11
PCT/US2017/012737 WO2017120591A1 (en) 2016-01-08 2017-01-09 Combination of a chromene compound and a second active agent

Publications (1)

Publication Number Publication Date
KR20180100652A true KR20180100652A (ko) 2018-09-11

Family

ID=59274050

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187022783A Ceased KR20180100652A (ko) 2016-01-08 2017-01-09 크로멘 화합물 및 제2활성제의 조합물

Country Status (9)

Country Link
US (2) US20170196835A1 (enExample)
EP (1) EP3400218A4 (enExample)
JP (1) JP6942726B2 (enExample)
KR (1) KR20180100652A (enExample)
CN (1) CN108779091B (enExample)
AU (1) AU2017206108B2 (enExample)
CA (1) CA3010848A1 (enExample)
MX (1) MX388579B (enExample)
WO (1) WO2017120591A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024172513A1 (ko) * 2023-02-16 2024-08-22 (주)재인알앤피 신규한 데커신 유도체, 및 이의 비소세포폐암 예방 또는 치료 용도

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220130249A (ko) 2016-05-26 2022-09-26 리커리엄 아이피 홀딩스, 엘엘씨 Egfr 억제제 화합물
CN110869055B (zh) * 2017-07-20 2023-04-28 国立大学法人北海道大学 靶向pd-1/pd-l1的抑制剂与cox-2抑制剂的组合使用
TR201900059A2 (tr) 2018-01-05 2019-07-22 Gnt Biotech & Medicals Corp Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem
TWI869398B (zh) * 2019-05-10 2025-01-11 英商拜西克爾德有限公司 治療癌症之方法
EP4051260A4 (en) * 2019-10-28 2023-12-06 Enzychem Lifesciences Corporation Methods and compositions for treatment of cancer
CN115135385B (zh) 2019-11-12 2024-05-10 纳米医疗有限公司 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法
CA3174675A1 (en) 2020-04-29 2021-11-04 Relay Therapeutics, Inc. Pi3k.alpha. inhibitors and methods of use thereof
EP4412606A4 (en) * 2021-10-07 2025-09-24 Relay Therapeutics Inc PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US20040127470A1 (en) 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
EP2175722A4 (en) 2007-07-12 2010-08-25 Tragara Pharmaceuticals Inc PATIENT SELECTION AND THERAPEUTIC PROCEDURES WITH PROSTAGLAND INMETABOLISM MARKERS
CN102757417B (zh) 2012-06-18 2014-09-24 中国科学院广州生物医药与健康研究院 氘代苯并吡喃类化合物及其应用
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN103012350B (zh) * 2012-12-07 2015-02-04 中国科学院广州生物医药与健康研究院 苯并吡喃类手性化合物的合成方法
CN103044477B (zh) 2012-12-07 2015-08-05 中国科学院广州生物医药与健康研究院 三甲基硅取代苯并吡喃类化合物及其应用
US9452228B2 (en) * 2013-04-01 2016-09-27 Immunomedics, Inc. Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
CN105073128A (zh) * 2013-04-03 2015-11-18 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US11034757B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024172513A1 (ko) * 2023-02-16 2024-08-22 (주)재인알앤피 신규한 데커신 유도체, 및 이의 비소세포폐암 예방 또는 치료 용도

Also Published As

Publication number Publication date
EP3400218A4 (en) 2019-09-18
JP2019501224A (ja) 2019-01-17
EP3400218A1 (en) 2018-11-14
JP6942726B2 (ja) 2021-09-29
CN108779091A (zh) 2018-11-09
CN108779091B (zh) 2022-12-27
CA3010848A1 (en) 2017-07-13
AU2017206108B2 (en) 2021-10-28
US20220265602A1 (en) 2022-08-25
AU2017206108A1 (en) 2018-08-02
MX388579B (es) 2025-03-20
MX2018008433A (es) 2019-03-28
WO2017120591A1 (en) 2017-07-13
US20170196835A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
US20220265602A1 (en) Combination of a chromene compound and a second active agent
JP2020169223A (ja) 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物
US11369623B2 (en) Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
KR20190067235A (ko) Vista 및 pd-1 경로의 이중 억제제
JP7246309B2 (ja) 免疫応答を調節するためのオキサビシクロヘプタン
EP3743061A1 (en) Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
JP2016539156A (ja) オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
CN110898226A (zh) Iap抑制剂与免疫检查点分子调节剂的组合用于治疗癌症的方法
WO2019241536A1 (en) Oxabicycloheptanes for enhancing car t cell function
CN119768393A (zh) Mek抑制剂和其用途
CN112121169A (zh) 用于治疗具有高间质压力的肿瘤受试者的癌症的小分子抑制剂
CN113316449A (zh) 胍那苄作为免疫疗法的佐剂
EP4408397A1 (en) Novel combination of serotonin receptor (5-htr) antagonist and an immunomodulator and chemotherapeutic drugs for inhibition of cancer
CA3214753A1 (en) Dosing of bispecific t cell engager
HK40000167B (en) Combination of a chromene compound and a second active agent
HK40000167A (en) Combination of a chromene compound and a second active agent
WO2023242098A1 (en) Novel ras inhibitors
HK40015605A (en) Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T12-X000 Administrative time limit extension not granted

St.27 status event code: U-3-3-T10-T12-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000